Markers of vitamin D metabolism and premenstrual symptoms in healthy women with regular cycles.
PMS
breast pain
generalized aches and pains
premenopausal women
premenstrual syndrome
vitamin D
Journal
Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199
Informations de publication
Date de publication:
18 06 2021
18 06 2021
Historique:
received:
14
01
2020
revised:
03
03
2021
pubmed:
18
4
2021
medline:
8
7
2021
entrez:
17
4
2021
Statut:
ppublish
Résumé
Are insufficient 25-hydroxyvitamin D (25(OH)D) concentrations, and other markers of vitamin D metabolism, associated with premenstrual symptoms in healthy women with regular menstrual cycles? 25(OH)D insufficiency was associated with specific physical premenstrual symptoms, while no associations were observed with psychological symptoms or with other markers of vitamin D metabolism. Prior studies evaluating vitamin D and premenstrual symptoms have yielded mixed results, and it is unknown whether 25(OH)D insufficiency and other markers of vitamin D metabolism are associated with premenstrual symptoms. We used two cohorts of women with regular menstrual cycles; 1191 women aged 18-40 years in EAGeR (cross-sectional analysis of a prospective cohort within a randomized trial) and 76 women aged 18-44 years in BioCycle (prospective cohort). In EAGeR, premenstrual symptoms over the previous year were assessed at baseline, whereas in BioCycle, symptoms were assessed prospectively at multiple points over two menstrual cycles with symptoms queried over the previous week. In both cohorts, symptomatology was assessed via questionnaire regarding presence and severity of 14 physical and psychological symptoms the week before and after menses. Both studies measured 25(OH)D in serum. We also evaluated the association of additional markers of vitamin D metabolism and calcium homeostasis, including intact parathyroid hormone (iPTH), calcium (Ca), fibroblast growth factor 23 (FGF23), and 1,25 dihydroxyvitamin D (1,25(OH)2D) with premenstrual symptoms in the BioCycle cohort. One cohort of women actively seeking pregnancy (Effects of Aspirin in Gestation and Reproduction (EAGeR)) and one cohort not seeking pregnancy (BioCycle) were evaluated. Log-binomial regression was used to estimate risk ratios (RR) and 95% CIs for associations between insufficient 25(OH)D (<30 ng/ml) and individual premenstrual symptoms, adjusting for age, BMI, race, smoking, income, physical activity, and season of blood draw. 25(OH)D insufficiency was associated with increased risk of breast fullness/tenderness (EAGeR RR 1.27, 95% CI 1.03, 1.55; BioCycle RR 1.37, 95% CI 0.56, 3.32) and generalized aches and pains (EAGeR RR 1.33, 95% CI 1.01, 1.78; BioCycle 1.36, 95% CI 0.41, 4.45), though results were imprecise in the BioCycle study. No associations were observed between insufficient 25(OH)D and psychological symptoms in either cohort. In BioCycle, iPTH, Ca, FGF23, and 1,25(OH) 2D were not associated with any premenstrual symptoms. Results from the EAGeR study were limited by the study design, which assessed both 25(OH)D at baseline and individual premenstrual symptoms over the past year at the baseline. As such, reverse causality is a potential concern. Though premenstrual symptoms were assessed prospectively in the BioCycle cohort, the power was limited due to small sample size. However, results were fairly consistent across both studies. Serum 25(OH)D may be associated with risk and severity of specific physical premenstrual symptoms. This work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland (Contract nos. HHSN267200603423, HHSN267200603424, and HHSN267200603426). JG.R. and D.L.K. have been funded by the NIH Medical Research Scholars Program, a public-private partnership jointly supported by the NIH and generous contributions to the Foundation for the NIH by the Doris Duke Charitable Foundation (Grant #2014194), the American Association for Dental Research, the Colgate Palmolive Company, Genentech, and other private donors. For a complete list, visit the foundation website at http://www.fnih.org. The authors have no conflicts of interest to disclose. Clinicaltrials.gov NCT00467363.
Identifiants
pubmed: 33864070
pii: 6231562
doi: 10.1093/humrep/deab089
pmc: PMC8530167
doi:
Substances chimiques
FGF23 protein, human
0
Vitamin D
1406-16-2
Fibroblast Growth Factor-23
7Q7P4S7RRE
Banques de données
ClinicalTrials.gov
['NCT00467363']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1808-1820Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201100002I
Pays : United States
Informations de copyright
Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology 2021. This work is written by US Government employees and is in the public domain in the US.
Références
Eur J Obstet Gynecol Reprod Biol. 2009 May;144 Suppl 1:S11-9
pubmed: 19285773
J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):434-7
pubmed: 20398756
J Womens Health (Larchmt). 2017 Oct;26(10):1099-1105
pubmed: 28650737
Paediatr Perinat Epidemiol. 2015 Mar;29(2):162-7
pubmed: 25682951
N Engl J Med. 1998 Mar 19;338(12):777-83
pubmed: 9504937
J Clin Diagn Res. 2014 Feb;8(2):106-9
pubmed: 24701496
Psychoneuroendocrinology. 2003 Aug;28 Suppl 3:1-23
pubmed: 12892987
Lancet. 2014 Jul 5;384(9937):29-36
pubmed: 24702835
J Chem Neuroanat. 2011 Jan;41(1):1-12
pubmed: 20969950
Breast Cancer Res Treat. 2011 Aug;129(1):107-16
pubmed: 21691817
Paediatr Perinat Epidemiol. 2013 Nov;27(6):598-609
pubmed: 24118062
Breast J. 2014 Mar-Apr;20(2):174-9
pubmed: 24467395
Obstet Gynecol. 2002 Jun;99(6):1014-24
pubmed: 12052592
J Am Coll Nutr. 2000 Apr;19(2):220-7
pubmed: 10763903
Fertil Steril. 2020 Dec;114(6):1278-1287
pubmed: 33066974
Breast Cancer Res Treat. 2016 Feb;155(3):501-12
pubmed: 26868123
Anticancer Res. 2009 Sep;29(9):3713-20
pubmed: 19667169
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Epidemiology. 1999 Jan;10(1):37-48
pubmed: 9888278
J Clin Oncol. 2008 Jul 1;26(19):3147-52
pubmed: 18474874
J Educ Health Promot. 2018 May 03;7:64
pubmed: 29922693
Hum Reprod. 2020 Feb 29;35(2):413-423
pubmed: 32068843
Am Fam Physician. 2016 Aug 1;94(3):236-40
pubmed: 27479626
Arch Intern Med. 2012 Feb 27;172(4):366-7
pubmed: 22371927
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Cancer Nurs. 2009 Mar-Apr;32(2):143-50
pubmed: 19125120
J Physiol Anthropol. 2009;28(3):129-36
pubmed: 19483374
J Reprod Med. 2003 Jul;48(7):515-24
pubmed: 12953326
Breast Cancer Res Treat. 2011 Feb;125(3):869-78
pubmed: 20665105
Arch Intern Med. 2005 Jun 13;165(11):1246-52
pubmed: 15956003
Mayo Clin Proc. 2011 Nov;86(11):1050-5
pubmed: 22033249
Am J Epidemiol. 2002 Jan 15;155(2):176-84
pubmed: 11790682
Miner Electrolyte Metab. 1995;21(1-3):217-22
pubmed: 7565453
Breast Cancer Res Treat. 2010 Jan;119(1):111-8
pubmed: 19655244
Breast Cancer Res Treat. 2017 Nov;166(2):491-500
pubmed: 28770449
Paediatr Perinat Epidemiol. 2009 Mar;23(2):171-84
pubmed: 19159403
Bone. 2016 Feb;83:248-255
pubmed: 26620084
Annu Rev Pharmacol Toxicol. 2011;51:311-36
pubmed: 20936945
BMC Womens Health. 2014 Apr 12;14:56
pubmed: 24725979